TABLE 4.
Associations between Mex3a mRNA levels and clinicopathological features in HCC.
| Parameter | Total number | mRNA level (%) | p-value |
|---|---|---|---|
| Gender | 0.313 a | ||
| Male | 147 | 12.692 (3.291–20.372) | |
| Female | 82 | 11.134 (2.413–16.652) | |
| Age (year) | 0.391 a | ||
| ≤55 | 111 | 11.949 (1.622–18.050) | |
| >55 | 118 | 12.885 (3.670–20.031) | |
| HBeAg | 0.432 a | ||
| Negative | 110 | 12.253 (3.137–21.190) | |
| Positive | 119 | 12.076 (3.027–16.536) | |
| HBV-DNA | 0.613 a | ||
| Negative | 124 | 12.175 (3.009–18.630) | |
| Positive | 105 | 12.221 (3.407–20.501) | |
| AFP (ng/mL) | 0.611 a | ||
| ≤20 | 96 | 11.400 (1.560–16.988) | |
| >20 | 133 | 12.221 (3.598–20.051) | |
| Primary tumor number | 0.680 a | ||
| Single | 104 | 12.309 (3.037–20.687) | |
| Multiple | 39 | 12.050 (2.751–18.384) | |
| Tumor size | 0.986 a | ||
| ≤5 cm | 152 | 12.065 (3.195–18.956) | |
| >5 cm | 77 | 12.310 (2.457–20.192) | |
| Lymph node metastasis | 0.352 a | ||
| Yes | 24 | 12.991 (9.259–20.031) | |
| No | 205 | 12.076 (3.009–18.930) | |
| Distant metastasis | 0.455 a | ||
| Yes | 19 | 10.010 (0.253–19.009) | |
| No | 210 | 12.265 (3.163–19.051) | |
| Vascular invasion | 0.833 a | ||
| Negative | 133 | 12.055 (3.112–20.231) | |
| Positive | 96 | 12.368 (3.061–16.988) | |
| CTP staging | 0.565 b | ||
| A | 166 | 12.382 (2.522–19.533) | |
| B | 53 | 12.198 (3.407–18.388) | |
| C | 10 | 4.835 (0.254–19.658) | |
| BCLC staging | 0.912 a | ||
| 0/1/2 | 111 | 12.055 (2.587–20.090) | |
| 3/4 | 118 | 12.368 (3.137–17.439) | |
| Ascites | 0.769 a | ||
| No | 161 | 12.221 (3.112–19.118) | |
| Yes | 68 | 12.124 (3.061–18.976) | |
| Encephalopathy | 0.974 a | ||
| No | 218 | 12.209 (3.053–18.990) | |
| Yes | 11 | 10.397 (3.455–25.010) |
CTP, Child–Turcotte–Pugh; BCLC, Barcelona Clinic Liver Cancer.
*p < 0.05.
**p < 0.01.
***p < 0.001.
a
Mann–Whitney U test.
b
Kruskal–Wallis H test.